PMID- 16946036
OWN - NLM
STAT- MEDLINE
DCOM- 20061018
LR  - 20231120
IS  - 1095-9203 (Electronic)
IS  - 0036-8075 (Print)
IS  - 0036-8075 (Linking)
VI  - 314
IP  - 5796
DP  - 2006 Oct 6
TI  - Cancer regression in patients after transfer of genetically engineered 
      lymphocytes.
PG  - 126-9
AB  - Through the adoptive transfer of lymphocytes after host immunodepletion, it is 
      possible to mediate objective cancer regression in human patients with metastatic 
      melanoma. However, the generation of tumor-specific T cells in this mode of 
      immunotherapy is often limiting. Here we report the ability to specifically 
      confer tumor recognition by autologous lymphocytes from peripheral blood by using 
      a retrovirus that encodes a T cell receptor. Adoptive transfer of these 
      transduced cells in 15 patients resulted in durable engraftment at levels 
      exceeding 10% of peripheral blood lymphocytes for at least 2 months after the 
      infusion. We observed high sustained levels of circulating, engineered cells at 1 
      year after infusion in two patients who both demonstrated objective regression of 
      metastatic melanoma lesions. This study suggests the therapeutic potential of 
      genetically engineered cells for the biologic therapy of cancer.
FAU - Morgan, Richard A
AU  - Morgan RA
AD  - Surgery Branch, Center for Cancer Research, National Cancer Institute, National 
      Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
FAU - Dudley, Mark E
AU  - Dudley ME
FAU - Wunderlich, John R
AU  - Wunderlich JR
FAU - Hughes, Marybeth S
AU  - Hughes MS
FAU - Yang, James C
AU  - Yang JC
FAU - Sherry, Richard M
AU  - Sherry RM
FAU - Royal, Richard E
AU  - Royal RE
FAU - Topalian, Suzanne L
AU  - Topalian SL
FAU - Kammula, Udai S
AU  - Kammula US
FAU - Restifo, Nicholas P
AU  - Restifo NP
FAU - Zheng, Zhili
AU  - Zheng Z
FAU - Nahvi, Azam
AU  - Nahvi A
FAU - de Vries, Christiaan R
AU  - de Vries CR
FAU - Rogers-Freezer, Linda J
AU  - Rogers-Freezer LJ
FAU - Mavroukakis, Sharon A
AU  - Mavroukakis SA
FAU - Rosenberg, Steven A
AU  - Rosenberg SA
LA  - eng
GR  - Z01 BC010763-01/Intramural NIH HHS/United States
GR  - Z01 SC003811-32/Intramural NIH HHS/United States
GR  - Z99 CA999999/Intramural NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20060831
PL  - United States
TA  - Science
JT  - Science (New York, N.Y.)
JID - 0404511
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Interleukin-2)
RN  - 0 (MART-1 Antigen)
RN  - 0 (MLANA protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
SB  - IM
CIN - Science. 2006 Oct 6;314(5796):68-9. PMID: 17023641
MH  - *Adoptive Transfer
MH  - Adult
MH  - Antigens, Neoplasm/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cancer Vaccines/therapeutic use
MH  - Cells, Cultured
MH  - Electroporation
MH  - Female
MH  - Genetic Engineering
MH  - *Genetic Therapy
MH  - HLA-A Antigens/immunology
MH  - HLA-A2 Antigen
MH  - Humans
MH  - Interleukin-2/immunology/therapeutic use
MH  - MART-1 Antigen
MH  - Male
MH  - Melanoma/immunology/secondary/*therapy
MH  - Middle Aged
MH  - Neoplasm Proteins/*immunology
MH  - Receptors, Antigen, T-Cell, alpha-beta/*genetics/*immunology
MH  - Transduction, Genetic
MH  - Transgenes
PMC - PMC2267026
MID - NIHMS35282
EDAT- 2006/09/02 09:00
MHDA- 2006/10/19 09:00
PMCR- 2008/03/12
CRDT- 2006/09/02 09:00
PHST- 2006/09/02 09:00 [pubmed]
PHST- 2006/10/19 09:00 [medline]
PHST- 2006/09/02 09:00 [entrez]
PHST- 2008/03/12 00:00 [pmc-release]
AID - 1129003 [pii]
AID - 10.1126/science.1129003 [doi]
PST - ppublish
SO  - Science. 2006 Oct 6;314(5796):126-9. doi: 10.1126/science.1129003. Epub 2006 Aug 
      31.